Compare Pfizer Inc (PFE) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Sony Group Corp — how do they compare? Pfizer Inc trades at $24.89 (market cap $142.14B), while Sony Group Corp trades at $20.89 (market cap $124.97B). The key difference: Pfizer Inc and Sony Group Corp are close in size by market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | SONY | |
|---|---|---|
Market Cap | $142.14B | $124.97B |
Volume | 29,869,932 | — |
Sector | Health | Technology |
52-Week High | $28.56 | $30.26 |
52-Week Low | $23.29 | $19.32 |
Enterprise Value | $192.80B | $121.48B |
Dividend Yield | 6.9% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Sony trades at $21.02, down 0.47% on the day. The stock shows a bullish technical signal with strong moving average alignment, though oscillators are neutral. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Revenue for 2025 was $12.96 trillion with a net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive with 11 buy ratings and no sell recommendations.
The outlook for Sony is mixed; strong cash flow and a solid balance sheet support growth in entertainment and AI investments, but the shift away from physical media and projected 2026 losses pose risks. Investor sentiment remains cautiously optimistic given the bullish analyst consensus and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
